Eli Lilly’s chief scientific officer said the company purchased a cancer drug from the startup Scorpion Therapeutics because it "checked all the boxes." ...
Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...
Hosted on MSN1mon
Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro"Our top priority is making more product, and we're doing everything we can to do that," Eli Lilly CEO David Ricks said in an interview Tuesday on CNBC's "Squawk Box." "We're ramping that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback